Nov. 8, 2013
/PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced the pricing of an underwritten public offering of 7,142,858 shares of its common stock, offered at a price of
per share to the public. The gross proceeds to DURECT from this offering are expected to be approximately
, before deducting underwriting discounts and commissions, and other estimated offering expenses payable by DURECT. All of the shares in the offering are to be sold by DURECT. The offering is expected to close on or about
November 13, 2013
, subject to the satisfaction of customary closing conditions. DURECT has granted the underwriters a 30-day option to purchase up to an aggregate of 1,071,429 additional shares.
Stifel is acting as sole book-running manager for the offering and
Janney Montgomery Scott
is acting as co-manager.
, our Chairman and Chief Scientific Officer, has agreed to purchase 714,000 shares of the 7,142,858 shares of common stock in this offering, at the public offering price, for an aggregate purchase price of approximately
A shelf registration statement on Form S-3 relating to the public offering of the shares of common stock described above was filed with the Securities and Exchange Commission (the "SEC") and is effective. A final prospectus supplement relating to the offering will be filed with the SEC and will be available on the SEC's web site at
. When available, copies of the final prospectus supplement may also be obtained from Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate,
One Montgomery Street
, Suite 3700,
San Francisco, California
94104, or by calling (415) 364-2500.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.